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Comments I
To the U.S. Government: Whether or not
Reimportation is the Answer, Something
MUST be Done to Help Americans Afford
Their Necessary Prescription Drugs!
Anthony F. Andrisano Jr.*
Roland and Carolyn Watson, 74 and 72 respectively, combine to
take thirty-two prescriptions for their numerous health disorders, which
include diabetes, renal failure, congestive heart failure, and Parkinson's
disease.' Although they have some coverage through a Kaiser
Permanente health plan and the Department of Veterans Affairs, they
still expend about $8,000 a year in out-of-pocket drug prescription
expenses. Unfortunately, Roland and Carolyn are not alone. There are
many American citizens, especially seniors, who are finding that they
* J.D. Candidate, The Dickinson School of Law of the The Pennsylvania State
University, 2005; B.S., Elizabethtown College, 2002. I would like to thank all of the
members of the Penn State International Law Review for their generous contributions to
this Comment. I would also like to thank Ms. Linda Williams of the Health Care Section
in the Pennsylvania Office of Attorney General for suggesting this topic to me. Lastly, I
would like to thank Kelly Sparvieri for taking the time to perform numerous edits
throughout the entire process of writing this Comment.
1. Abigail Trafford, Second Opinion: The Great Pharmacy to the North, THE
WASHINGTON POST, Sept. 30, 2003, at HE01.
2. Id.
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need to choose between taking essential medications and paying for the
basic necessities of life.3 In fact, approximately twenty percent of
Americans are unable to afford some or all of their prescription drugs.
4
Moreover, these skyrocketing health costs are also posing serious
challenges to many city, state, and federal budgets.5  Congress
continually fails to address this critical issue and many Americans, like
Roland and Carolyn Watson, are turning to foreign countries, such as
Canada or Mexico, to fulfill their prescription needs.6
Turning to foreign markets allow Americans, on average, to
purchase their necessary prescription drugs for forty percent less than in
the American market.7 For example, Actos, which treats diabetes, sells
in the United States for $516.63. The same quantity of Actos sells in
Canada for only $268.52, amounting to a forty-eight percent difference.8
Similarly, a three-month supply of the anti-cholesterol drug Lipitor, the
world's top-selling prescription drug, sells in the United States for $208.
Canada sells the same quantity of the drug for only $132, amounting to a
thirty-seven percent difference. 9 These vast differences in prices on top
3. Jarret T. Barrios and Michael Festa, A Free Market for Medicines, BOSTON
GLOBE, Sept. 21, 2003, available at http://www.boston.com/news/globe/
editorialopinion/oped/articles/2003/09/21/a freemarket for medicines?mode=PF (last
visited Feb. 15, 2005). One elderly woman regularly signed over her Social Security
check to the pharmacy to pay for a blood thinner. Id. The nurse that collected this story
stated that the elderly woman's doctor "openly wondered how she found food to eat." Id.
4. State Should Join Drug Price Revolt; Tens of Millions of Dollars Could Be
Saved On Health Costs for Workers and Retirees, SAN JOSE MERCURY NEWS, Sept. 21,
2003, available at http://www.affordabledrugs.il.gov/article.cfm?RecNum=53 (last
visited Feb. 15, 2005).
5. Wyn Snow, FDA Strangling Consumer Health (Nov. 6 2003), available at
http://www.supplementquality.com/news/ skyrocketing.drug-costs.html (last visited Feb.
15, 2005). While the high cost of prescription drugs may only be the "tip of the iceberg,"
(concerning city, state and federal budgets) "it is the most visible and easiest to attack."
Id.
6. Trafford, supra note 1.
7. Joe Biesk, Auditor: State could save millions by importing drugs, LEXINGTON
HERALD-LEADER, Sept. 28, 2004, available at http://www.kentucky.com/mld/kentucky/
news/local/9781516.htm (last visited February 15, 2005). There are various other reports
on the percentage Americans can receive from purchasing their prescription drugs from
Canada with some sources asserting that prescription drugs reimported from Canada are
up to seventy-seven percent cheaper. See Bloomberg News, Drugfirms sued over prices,
Suit says Canadian medicines kept out, Aug. 27, 2004, available at
http://www.boston.com/business/markets/articles/2004/08/27/drug-firms-sued -over-pric
es/ (last visited Feb. 15, 2005).
8. Tim Jones, Seniors find Canada is Refuge from Drug Prices; U.S. costs leave no
choice, they say. CHICAGO TRIBUNE, Sept. 21, 2003, at 1. These are only two of the many
examples within this article-the price comparisons are based on prices taken on July 16,
2003 at Walgreen's in the United States and at the MediMart Pharmacy in Canada. Id.
9. Drugs up to 80 percent cheaper in Canada, PROVIDENCE JOURNAL-BULLETIN,
Nov. 6, 2003, at A10. This is one example of the ten prescription drugs that were
surveyed and found to be up to eighty percent cheaper in Canada-the prices from
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of the current economic conditionsl° encourage Americans, especially
those struggling to make ends meet, to explore their options in pursuing
their prescription drug needs from foreign markets.
These options, or reimportation I" channels, have become extremely
easy to utilize. At first, any American who wished to exploit the cheaper
Canadian prices had to travel across the border, find a Canadian doctor
willing to rewrite the prescription, and then take the prescription to a
Canadian pharmacy. 12 Approximately ten million United States citizens
per year utilize this reimportation channel and personally reimport their
prescription drugs into the United States.13 While this channel genuinely
helps those Americans who happen to live reasonably close to a foreign
border, it does very little for those Americans living farther away.1
4
The Internet has proven to be another useful means of obtaining
prescription drugs, because it allows individuals to simply go to an
Internet website and order the necessary prescription drugs.15 In 2003,
Canada were taken from CanadaRx, a Toronto-based company, and the United States
prices were taken from the Web sites of CVS Corporation and Walgreen Company. Id.
The biggest price difference came from the antipsychotic drug Risperdal, which was
eighty percent cheaper in Canada. Id.
10. The weakness of the Canadian dollar favors Americans. See Nicolas P. Terry,
Prescriptions sans Frontieres (or How I Stopped Worrying About Viagra on the Web but
Grew Concerned About the Future of Healthcare Delivery), 4 YALE J. HEALTH POL'Y, L.
& ETHICS 183, 207 (2004).
11. John A. MacDonald, Drug Battle Heats Up, THE HARTFORD COURANT, Sept. 18,
2003. Experts use the term reimportation because most prescription drugs are
manufactured in the United States, sent to other countries, where price controls are in
effect, and then reimported by Americans looking for savings. Id.
12. Id. United States Senator Mark Dayton pays for seniors Americans to take bus
trips to Canada. Id. The seniors would bring their prescriptions written by a U.S.
physician, have a Canadian physician rewrite the prescription, and then submit it to a
Canadian pharmacy. Id. See also Markian Hawryluk, Drugs Without Borders: When
Prescription Drugs Go over the Line, AMNEWS.COM, (Oct. 22/29, 2001), available at
http://www.amednews.com/2001/gvsa1022 (last visited Feb. 15, 2005). This article
demonstrates that many political candidates and seniors groups from northern states have
organized bus trips to purchase Canadian prescription drugs. Id.
13. Terry, supra note 10, at 203 (citing Mary Pat Flaherty & Gilbert M. Gaul,
Millions of Americans Look Outside U.S..for Drugs, THE WASHINGTON POST, Oct. 23,
2003, at Al). In order to save money, many individuals or organizations organized bus
trips to Canada. Mike Hall, What Drug Companies Aren't Telling YOU, available at
http://www.aflcio.org/aboutaflcio/magazine/0503_bigfix.cfm (last visited Feb. 15, 2005).
For example, the Alliance for Retired Americans organized a bus trip to Canada, which
entailed 375 seniors saving more than half a million dollars on their prescription drugs.
Id.
14. For instance, a resident in the middle of Kansas would find it extremely hard to
routinely travel across the Canadian or Mexican border simply to obtain prescription
drugs. But see Hawryluk, supra note 13. In a survey taken at a Mexican border crossing,
one doctor observed individuals from thirty-seven different states reimporting
prescription drugs. Id.
15. For a more in-depth analysis of Internet pharmacies, see Linda C. Fentiman,
Internet Pharmacies and the Need for a New Federalism. Protecting Consumers While
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approximately eighteen percent of online United States households
purchased prescription drugs online, a number that is expecting to rise to
twenty-seven percent in 2004.16 Even with these rising statistics, many
Americans, especially seniors, are still finding it very difficult to obtain
affordable prescription drugs.17  Most Senior Americans are not
particularly Internet savvy and, thus, are unable to take advantage of the
ease the Internet provides
1 8
Furthermore, some Americans are deterred from using Internet
suppliers because there has been evidence that some Internet drug
suppliers pretend to be based in Canada when they are actually based in
other countries that do not have the same safeguards as the United States
or Canada.' 9 Many of these Internet suppliers obtain their prescription
drugs illegally from wholesalers or by other undisclosed, unregulated
sources that have been deemed counterfeit.20  For instance, in Florida,
nineteen people were indicted on charges of watering down or selling
counterfeit drugs to fulfill prescriptions for consumers through Internet
businesses.2' Moreover, the National Association of Boards of
Pharmacies estimates that only 275 of the 400 U.S.-based online
pharmacies in operation offer legitimate prescription drugs; the
remainder having undetermined business practices.22
An entrepreneur, Carl Moore, recognized these problems and
attempted to rectify them by establishing storefront distributors across
Increasing Access to Prescription Drugs, 56 RUTGERS L. REv. 119, 126-132 (2003).
16. Terry, supra note 10 at 183 (citing Eric G. Brown with Bradford J. Homes et al.,
Forrester's Top 10 Healthcare Predictions for 2004 (December 15, 2003), available at
http://www.forrester.com/ER/Research/Brief/0,1317,33444,00.html (last visited February
15, 2005)).
17. Theresa Agovino, Entrepreneur Fills an Order for Trouble, ST. Louis POST-
DISPATCH, Oct. 8, 2003.
18. Id. The owner of the original storefront distributor, Rx Depot, first operated a
website offering the same service, but, because most of his customers were seniors and
not particularly Internet savvy, few were utilizing the website. Id.
19. Terry Hillig, Critics are wary of Illinois' Drugs-From-Canada, ST. Louis POST-
DISPATCH, Sept. 20, 2003. This article quotes Mike Patton, a spokesman for the Illinois
Pharmacists Assoc., stating that "some suppliers of drugs on the Internet pretend to be
based in Canada when they are actually [based] in other countries." Id.
20. Jack Nicolis, Don't Allow Import of Canadian Drugs, THE JOURNAL NEWS (New
York) Nov. 17, 2003. A report by a United States research firm found that only thirty
percent of Canadian Internet pharmacies selling prescription drugs to United States
citizens were not affiliated with any licensed pharmacy. Id.
21. Steve Stanek, Illinois Gov. Ignores Rx Warning, HEALTH CARE NEwS, Nov.
2003, at 17. In addition to the Florida indictment, a counterfeit version of Pfizer's Lipitor
was discovered in Nebraska after pharmacists and patients complained the medicine
tasted unusually bitter and dissolved too quickly. Id.
22. Anna Wilde Matthews and Nick Wingfield, Drugstore.com Battles Portals with
Imported-Drug Ads, WALL ST. J., Oct. 31, 2003. Additionally, only fifteen of the four-
hundred U.S.-based online pharmacies are certified by state regulators. Id.
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the United States.23 These storefront distributors, known as Rx Depot or
Rx Canada,24 became the easiest and most popular channel for
Americans to reimport prescription drugs from Canada. An American
seeking less expensive prescription drug prices simply needed to go to
one of the storefront distributors, hand over a prescription, pay a cheaper
price, and wait for the prescription to arrive.25 As this comment will
further express, a recent District Court decision has eliminated the use of
Storefront Distributors,26 further hindering many Americans search for
affordable prescription drugs.
The overall reimportation concern is very complex and involves
many significant issues. This Comment intends to address many of these
reimportation issues by breaking each issue into easily understood
components.27 Part I of this Comment will provide an overview of the
reimportation debate, addressing the concerns expressed by those in
favor of reimportation and by those who oppose it. Part II will address
the actions the states have taken on this issue of reimportation. Part III
will give an in-depth synopsis of the judicial action taken by the FDA
through the Department of Justice. Finally, Part IV of this Comment
concludes with a brief assessment of the 2003 Medicare Prescription
Drug Improvement and Modernization Act2" and provides a suggestion
on how to deal with the issue of reimportation.
I. The Reimportation Debate
The United States is the only industrialized country where drug
manufacturers set prices without government interference. 29 This "free
market system" 30 allows a pharmaceutical company to determine and set
23. Id. Carl Moore is the founder of a chain of approximately eighty-five storefront
distributors, known as Rx Depot or Rx of Canada. Id.
24. Id.
25. Gardiner Harris, U.S. Moves to Halt Import of Drugs From Canada, N.Y. TIMES,
Sept. 10, 2003, at C2. Rx Depot has now accumulated eighty-five stores in twenty-six
states.
26. See discussion infra Part III.
27. Canada is the country that most Americans and storefront distributors import
prescription drugs from. Therefore, this Comment will direct its attention mainly to
issues concerning the reimportation of drugs from Canada-although other countries will
also be discussed.
28. The Medicare Prescription Drug Improvement and Modernization Act of 2003,
Pub. L. No. 108-173, 117 Stat. 2066.
29. Gardiner Harris, Pfizer Moves to Stem Canadian Drug Imports, N.Y. TIMES,
Aug. 7, 2003, at Cl, Col. 2. The pharmaceutical industry earns approximately half of its
revenues and most of its profits in the United States because, unlike other industrialized
nations, the United States government does not control drug prices. Id.
30. A free market system involves companies setting the price of their products
according to what they think the market will bear. Helkei Tinsley, Comment,
Prescriptions without Borders. American looks to Canada for Answers to Solve the
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the price for its prescription drugs without having to provide any
justification for its choice. 31 This has resulted in a substantial increase in
the price of prescription drugs in the United States. 32  For instance,
between 2002 and 2003, the price of Zocor and Pravacho 33 rose ten to
eleven percent.34 In fact, the price of prescription drugs in the United
States has increased seven to eight times the standard rate of inflation in
America.35
Other countries, such as Canada, are not troubled with similar
pricing problems because their governments' set price controls on
prescription drugs by negotiating directly with pharmaceutical
companies. 36 The pharmaceutical companies are forced to negotiate with
these countries because, otherwise, they would be unable to sell in these
foreign markets.37 In the past, the pharmaceutical companies were able
to tolerate these negotiated differences in profits because their profits in
America were so substantial that it did not matter that the rest of the
world was buying the drugs at a discount. 38  With more and more
Americans buying their prescription drugs through cheaper reimportation
channels, the pharmaceutical industry has changed its attitude, and is,
again,39 undertaking an extensive lobbying campaign4 ° to help nullify
Prescription Drug Pricing Predicament in the U.S., But is Importation Really the
Solution?, 25 HAMLINE J. PUB. L. & POL'Y 437, 440 (2004).
31. Id.at440-441.
32. Id. at 442.
33. Both are cholesterol drugs.
34. Tinsley, supra note 30, at 442 (citing U.S. Representative Dan Burton (R-IN)
Holds Hearing on Canadian Drug Importation before the House Comm. on Government
Reform, Subcomm. on Human Rights and Wellness, 10 8th Cong. 10 (June 25, 2003)
(testimony of U.S. Representative Gil Gutknecht (R-MN))). Further, Claritin, before
going over-the-counter, rose twenty-one percent between 2002-2003. Id.
35. Id. (citing U.S. Senator John McCain (R-AZ) Holds Hearing on Cost of
Prescription Drugs and Drug Importation. Before the Science and Transportation
Comm., Subcomm. of S. Commerce, 108th Cong. 41 (2003) (testimony of Senator Snowe
(R-ME))).
36. Id. at 447-48. Canada controls prescription drug prices by forcing
pharmaceutical manufacturers to disclose confidential information concerning their drug
pricing; based on this disclosure, the Canadian government determines an affordable
wholesale price that would give a reasonable return on the patented drug. Id. (citing Jerry
Stanton, Comment, Lesson for the United States from Foreign Price Controls on
Pharmaceuticals, CONN. J. INT'L. L. 149, 160 (2002)).
37. Tinsley, supra note 30, at 448.
38. Nina Owcharenko, Why Drug Importation is Bad Policy, HEALTH CARE NEWS,
Nov. 2003, at 9.
39. It is important to note that, after an expensive lobbying campaign in 1987, the
pharmaceutical industry won a battle in Congress that banned the reimportation of
prescription drugs into the United States. See Barrios and Festa, supra note 3. Since
then, Congress has enacted the Medical Equity and Drug Safety Act (MEDSA), which
gives the Secretary of Health and Human Services the power to allow the reimportation
of prescription drugs as long as the Secretary demonstrates that these imports would pose
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41
any efforts of legalizing reimportation.
The United States Food and Drug Administration (FDA) has taken
the side of the pharmaceutical industry by warning that reimportation of
42drugs presents a serious safety risk to the health of Americans. FDA
Commissioner Mark McClellan actually has warned that importation
"creates a wide channel for large volumes of unapproved drugs and other
products to enter the United States that are potentially injurious to public
health and pose a threat to the security of our Nation's drug supply. 43
While the FDA understands that reimportation allows Americans to save
money, it also realizes that "it has taken many years to build up the
safety system we now have in place, and it is misguided to think it can be
drastically changed quickly without negative consequences.
' 4
Notwithstanding the FDA's position, the House of Representatives
passed the Gutknecht-Emerson bill45 that would legalize imports of drugs
from Canada and some other industrialized countries.46 Although the
Senate has opposed this exact bill,47 it illustrates that there is
no additional health risks and that the imports would result in cost reductions in the
United States. See Tinsley, supra note 30, at 453-54. Although this law was enacted in
2000, no Secretary (under the Clinton or the Bush Administration) has attempted to
implement it. Id.
40. See Terry, supra note 10 at 210.
41. See discussion infra Part I.B.2.C.
42. It is important to note that the FDA has an "enforcement discretion policy"
whereby the FDA can choose to not enforce the Federal Food, Drug and Cosmetic Act
(FDCA) against individuals who travel to Canada or use the Internet to purchase
prescription drugs from Canada for personal use. See, 21 U.S.C. § 956(a) (2004). See
also Julie Appleby, Firm fights for Canadian drugs; Justice Department lawsuit against
U.S. Storefront-Rx Depot gains wide attention, USA TODAY, Oct. 7, 2003, available at
http://www.usatoday.com/money/industries/health/drugs/2003-1 0-06-rxdepot-x.htm (last
visited Feb. 7, 2005). The FDA's "personal use policy" gives United States residents the
ability to reimport ninety-day supplies of drugs not available in the United States to treat
serious conditions. Id. According to University of Texas Professor Marven Shepherd,
twenty-five to forty percent of all U.S. residents who travel to Mexico bring back
prescription pharmaceuticals. Hawryluk, supra note 12.
43. Grace-Marie Turner, Why Drug Importation Endangers the Country's Drug
Supply, HEALTH CARE NEWS, Nov. 2003, at 8. The FDA believes that allowing drug
imports from Canada and other countries will open United States borders to unsafe,
counterfeit, and contaminated drugs.
44. Marc Kaufman, FDA 's Authority Tested Over Drug Imports; At Issue Is Whether
Agency Will Lose Role in Assessing Safety of Medications, THE WASHINGTON POST, Nov.
9, 2003, at All. This is a quote from the FDA Commissioner Mark McClellan about
how safety will be compromised if consumers continue to import drugs from foreign
countries. Id.
45. Pharmaceutical Market Access Act of 2003, H.R. 2427, 108th Cong. § 2(3).
Unenacted bill passed by the House of Representatives on July 21, 2003 that legalizes the
importation of prescription drugs from Canada and other industrialized nations. Id.
46. Scott Hensley, Drug Makers Cry "Danger" Over Imports, WALL ST. J., Sept. 22,
2003. This act was passed by a vote of 243-186. Id.
47. MacDonald, supra note 11.
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overwhelming support for legalizing the reimportation of prescription
drugs. The crux for this argument is that "an unaffordable drug is neither
safe nor effective," and "allowing and structuring the importation of
prescription drugs ensures access to affordable drugs, thus providing a
level of safety to American consumers.,
48
A. Arguments Against Importation
l. Safety
Opponents core argument against reimportation lies with the issue
of safety. "In our experience, many drugs obtained from foreign sources
that purport and appear to be the same as FDA-approved prescription
drugs have been of unknown quality. 4 9 The only way to ensure the
safety of prescription drugs is to obtain the drugs within the United
States; this helps to guarantee that the drugs were tracked and approved
by the FDA.5° Many pharmacies in other countries do not necessarily
follow the same standards or have the same safeguards as those in the
United States.51 Furthermore, many of the drugs obtained outside of the
United States are counterfeit and some of the drugs sold overseas do not
even have an active ingredient.
In support of this argument, FDA associate Commissioner, William
Hubbard, has said that FDA inspectors and undercover investigators have
found numerous instances in which medications alleged to have come
from legitimate Canadian pharmacies were counterfeit, mislabeled or
expired.53 For instance, in Springfield, Massachusetts, the FDA staged
an unusual sting operation in which agents bought insulin from CanaRx,
48. See Pharmaceutical Market Access Act of 2003, H.R. 2427, 108th Cong. § 2(3).
49. MacDonald, supra note 12. This is a quote from associate commissioner of the
FDA, William K. Hubbard, which was taken from a seven-page letter addressed to the
deputy attorney general of California showcasing the FDA's opposition to importation.
Id.
50. Leslie Boyd, High medicine costs have some shopping across the border, THE
CITIZEN-TIMES (North Carolina), Sept. 19, 2003, available at http://cgi.citizen-
times.com/cgi-bin/story/wncbusiness/42089 (last visited February 7, 2005). Michael
Overman, owner of Lord's Pharmacy and a former member of the North Carolina
Pharmacy Board, believes that the only way to ensure the safety of prescription drugs is
to obtain them within the United States. Id.
51. Id.
52. Id. David Work, director of the North Carolina Pharmacy Board, is quoted as
saying "there are a lot of counterfeit drugs outside the United States, and there are drugs
being sold overseas that do not have an active ingredient."
53. Ceci Connolly, Iowa Plans to Procure Drugs From Canada; State Joins
Growing Group Seeking Cheaper Medicines Outside the U.S., THE WASHINGTON POST,
Sept. 24, 2003, at A02.
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an Ontario-based supplier of imported drugs.54 The insulin arrived at
room temperature, which does not comply with the crucial requirement
that insulin be kept refrigerated. 5
In May 2003, the FDA made an undercover purchase through Rx
Depot, a storefront distributor, by downloading the necessary Rx Depot
order forms and related paperwork from the Rx depot website.56 The
agent filled out the forms as though he was a patient, took the forms to
Rx Depot storefront distributor and placed an order for a 100-pill
package of the FDA-approved prescription drug Serzone. 7 Although the
prescription the agent used only authorized sixty pills, the agent was able
to order the 100-pill package offered on the Rx Depot website.5 In late
May 2003, the agent received a package from Pharmacy North, Inc., in
Winnipeg, Manitoba, Canada that contained ninety-nine pills of a
foreign-manufactured version of Serzone known as APO-Nefazodone.59
APO-Nefazodone is not generally recognized among qualified experts as
being safe and effective and it does not have FDA approval of any new
drug or abbreviated new drug.60 In addition, the labeling provided by the
Canadian pharmacy was far less descriptive in warning against the
potential side effects than the FDA-approved packaging insert for
Serzone.6'
Additionally, a spot inspection conducted by FDA agents in the
summer of 2003 "illustrated the real and serious health risks created by
the importation of unapproved drugs. 6 2 The spot inspections occurred
54. MacDonald, supra note 11. The article illustrates the veracity of the FDA's
safety argument by providing an example of how reimportation can be dangerous. Id.
55. Id.
56. United States v. Rx Depot, 290 F.Supp.2d 1238, 1242-43 (N.D.Okla. 2003).
This example was presented as evidence in the Northern District Court of Oklahoma by
the Department of Justice to showcase the danger of allowing reimportation. Id. Also see
discussion infra Part III.
57. Rx Depot, 290 F.Supp.2d at 1242-43.
58. Id.
59. Id. Even though the agent received only ninety-nine pills, the package was
labeled as containing one hundred pills. Id.
60. Id. at 1243. APO-Nefazodone does not have FDA approval of any new drug or
abbreviated new drug applications filed pursuant to 21 U.S.C. Sections 355 (b) or (j) and
it does not have in effect a valid exemption from such approval requirements under 21
U.S.C. Section 355(i). Id.
61. Id. The Canadian instructions do not specify some of the liver failure symptoms
listed on the Serzone insert. For example, it does not mention drugs that should be
avoided when taking APO-Nefazodone and it does not convey the sense of urgency
reflected in the Serzone insert. These substandard instructions could increase the risk of
adverse events, including life-threatening liver failure.
62. Gardiner Harris, F.D.A. Faults Quality of Imported Drugs, N.Y. TIMES, Sept. 30,
2003, available at http://www.aei-brookings.org/dailyregreport/archives/O08592 .php.
This quote is taken from Mark B. McClellan, the commissioner of the FDA, after
evaluating the results of a random spot inspection. Id.
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over two three-day periods at mail processing centers in Miami, New
York, San Francisco and Carson, California. The inspectors pulled out
1,153 packages that appeared from the outside to contain drugs and
found that approximately 1,019 or eighty-eight percent of the packages
contained unapproved drugs.
63
In light of these facts, opponents of reimportation argue that
encouraging American consumers to purchase prescription drugs from
foreign sources is counter to public policy, and that the public should
know that reimportation is simply unsafe. 64 In addition, American
consumers must realize that they may waive their legal rights, at least
with respect to the United States court system, if they suffer an injury by
a prescription drug purchased directly from Canada.65
The crux of this argument is that the United States has a unique,
closed system of drug distribution regulated by the FDA that protects
Americans from counterfeit, mislabeled or otherwise adulterated drugs
coming from unapproved foreign sources. Other countries, such as
Canada or Mexico, do not necessarily have the same regulations or
safeguards. In fact, many foreign countries do not purchase their
prescription drugs solely from the United States; they acquire many of
their drugs from the world market.66 Even though many foreign
countries have safe drug distribution systems in place,6 7 safety concerns
still arise when drugs move across borders because they are not under the
monitoring and control of any regulatory agency.68 This creates an
opportunity for unscrupulous merchants to slip unapproved drugs into an
otherwise safe distribution system,69 which makes it virtually impossible
63. Id.
64. Nicolis supra note 20. Believing reimportation to be illegal because it is unsafe,
this article addresses LePharmacy.com's announcement that it would be opening a
storefront in Westchester County. Id.
65. Position Paper, Importation of Foreign Prescription Drugs, National Association
of Boards of Pharmacy, March 2003, available at http://www.nabp.net/ftpfiles/NABP01/
foreigndrug.pdf (last visited Feb. 7, 2005). If a problem with a prescription drug
purchase from Canada actually occurs, there is little or no recourse because the actual
dispenser or prescriber may be unknown. Id. Additionally, the National Board of
Pharmacy has discovered that most, if not all, Canadian Internet pharmacies require
United States, but not Canadian, patients to waive their right to sue if a medication error
occurs. Id.
66. Nicolis supra note 20.
67. Bernard Simon, Canada Rebuffs U.S. on Prescription Drugs, N.Y. TtMEs, Nov.
19, 2003, available at http://www.globalaging.orgihealth/world/canadadrug2.htm (last
visited Feb. 7, 2005). The Canadian Government refused to clamp down on exports of
prescription drugs to the United States because it asserts that "Canada's safety record is
second to none internationally," and that the exports do not violate Canadian law. Id.
68. Kaufnan, supra note 44, at Al 1. The FDA uses this point to dismiss any claim
that Canadian drugs are safe because Canada has similar safety standards as those within
the United States.
69. Id.
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to control the flow of unapproved products into the United States.
Opponents of reimportation rightfully argue that this clearly poses a
serious threat to the health of Americans, because it allows the drug
supply of the United States to be contaminated.
2. Intellectual property rights
Opponents of the reimportation of prescription drugs also argue that
reimportation violates the United States Constitutional rights of
pharmaceutical companies. ° While cheaper drug prices sound like a
good idea, they can wind up destroying the free-market motivation that
produced the public good in the first place.71 Pharmaceutical companies
in the United States sink millions of dollars into research, testing,
development, and patents to produce some of the most sophisticated,
effective, and safe medicines in the world.72 A recent study by the Tufts
Center for the Study of Drug Development found that pharmaceutical
manufacturers spend around $897 million to develop a new drug.73 If
these drugs are sold for below market value, then who is going to pay for
the pharmaceutical companies heavy investment in research,
development, and production? 74 More precisely, who will pay the drug
companies for their property rights from which the public benefits?
Article 1, Section 8 of the United States Constitution authorizes
Congress "to promote the progress of science and useful arts, by securing
for limited times to authors and inventors the exclusive right to their
respective writings and discoveries. 75  Furthermore, the Fifth
Amendment states that ". .. [n]or shall private property be taken for
public use, without just compensation. ', 76  If Americans are able to
reimport drugs from Canada for cheaper prices, then these
aforementioned rights of pharmaceutical companies would be manifestly
violated.77 Additionally, the pharmaceutical companies will most likely
70. Nancie G. Marzulla, The Property Rights Pill: Why It's Good Medicine, Urban
Spectrum, Oct. 2003, available at http://www.defendersproprights.org/regulatory/
030924.asp (last visited Feb. 7, 2005). This article, written by the President of Defenders
of Property Rights, addresses the constitutional protection of the pharmaceutical
companies' intellectual property rights. Id.
71. Id.
72. Id.
73. Owcharenko, supra note 38, at 9. Only one out of every five drugs that reach
human trials ultimately will be approved for marketing. Id. This crucial investment in
research and development is supported by market-oriented countries (such as the United
States), and is thwarted by governments in price-controlling countries (such as Canada).
Id.
74. Compare discussion infra Part I.B.2.
75. U.S. Const. art. I, § 8.
76. U.S. Const. amend. V.
77. Marzulla, supra note 71.
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suffer losses, which, in turn, will force the industry to be unable to utilize
its resources in the research and development of new, innovative
prescription drugs.
Furthermore, one of the reasons many pharmaceutical companies
are located within the United States is because of the country's
commitment to protecting intellectual property rights.78 Both inventors
and investors have always been confident that the laws and Constitution
of the United States will protect their inventions and their investments.79
Opponents of reimportation believe that by allowing reimportation, the
United States will undoubtedly diminish confidence in the free-market
motivation that has always existed by creating a chain of events that
would weaken the intellectual property rights of pharmaceutical
manufacturers.8 °
This chain of events will first start with Canadian pharmacies
reimporting prescription drugs to United States citizens, which logically
will result in less prescription drug sales within the United States. In an
attempt to prevent this from occurring, the pharmaceutical companies
will limit, if not completely cut-off, its sales to Canadian pharmacies."
The Canadian government would then have to negotiate with a generic
manufacturer to produce or sell the drugs the country would need to
satisfy the prescription needs of its citizens. These generic companies
would most likely not obtain the approval of the pharmaceutical
company that holds the patent, which would allow the generic company
to make profits from a drug that it has spent very little, if any, money in
researching or developing. 82 This, in turn, would weaken United States
intellectual property rights, because the United States patent holder
would have incurred the expense of researching and developing the drug
while a foreign generic company was able to reap the benefits. This
weakened respect for intellectual property rights, a serious unintended
consequence of allowing reimportation, would create repercussions that
most likely would be felt worldwide.
83
78. Id.
79. Id.
80. Owcharenko, supra note 38, at 9. This article states that the allowing
reimportation of prescription drugs will create the serious unintended consequence of
weakening intellectual property rights, which would cause severe repercussions that
would be felt worldwide. Id.
81. See Ceci Connolly, Pfizer Cuts Supplies to Canadian Drugstores-Sales Are
Halted to Reimporters of Bargain Drugs, THE WASHINGTON POST, Feb. 19, 2004, at A10.
Pfizer, the world's largest drug manufacturer, wrote a letter to Winnipeg-based Universal
Drug Store and half a dozen other companies informing them that "effective
immediately, your pharmacy is no longer approved to purchase Pfizer products from
Pfizer Canada's authorized distributors." Id.
82. Id.
83. Id.
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The pharmaceutical companies could assert various International
agreements such as the WTO Agreement on Trade-Related Aspects of
Intellectual Rights (TRIPS) 84 and the North American Free Trade
Agreement (NAFTA),85  which require governments to protect
intellectual property rights because of the common recognition that
86
strong property rights protection fosters an effective trade regime.
Those countries that are part of these trade agreements, however, are able
to circumvent patent protections by declaring a national health
emergency, which, basically, strips a patent from a particular
pharmaceutical company and allows a generic manufacturer to steal the
formula and produce a generic drug.87  For example, the African
government was able to circumvent patent protections and purchase
generic prescription drugs, without violating TRIPS or NAFTA, by
declaring a national health emergency due to the rise in AIDS cases
within the country.
88
A similar situation would exist if United States pharmaceutical
companies decided to boycott prescription drug sales to Canada. Canada
most likely would be unable to provide its citizens with the proper
prescription drugs, which, in turn, would give the Canadian government
the right to declare a national health emergency and allow Canada to
circumvent TRIPS's and NAFTA's patent protections by purchasing
generic prescription drugs. This would allow foreign companies to sell
these generic drugs and reap the benefits of the drug in violation of the
patent held by the pharmaceutical company responsible for researching,
developing, and producing the drug.
While this may not violate an international treaty, opponents of
reimportation believe it discourages drug companies from developing
new drugs and, thus, creates repercussions worldwide. Why would a
pharmaceutical company spend exorbitant amounts of money on
researching and developing new drugs when it can simply wait for
another company to do so and then steal the formula to sell to foreign
countries? Opponents of reimportation adamantly answer this question
by saying "they won't." These companies will not expend money if the
84. Agreement of Trade-Related Aspects of Intellectual Property Rights, Apr. 15,
1994, Marrakesh Agreement Establishing the World Trade Organization, Annex 1C, 108
Stat. 4809, 1869 U.N.T.S. 299, 326.
85. North American Free Trade Agreement, Dec. 17, 1992, Can.-Mex.-U.S., 107
Stat. 2057, 32 I.L.M. 605.
86. Marzulla, supra note 70.
87. Id. Although taken away, certain individual countries, at one time, were able to
invalidate certain patents for particular reasons. See Luke W. Cleland, Modern
Bootlegging and the Prohibition on Fair Prices: Last Call for the "Repeal" of
Pharmaceutical Price Gouging, 15 ALB. L.J. Sci. & TECH. 183, 201 (2004).
88. Marzulla, supra note 70.
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traditional intellectual property protections are not in place. This, in turn,
would carry worldwide repercussions because the pharmaceutical
industry would put less money in the research and development of new
drugs-which hinders the advancement of medicine.
B. In Favor of Importation
1. It is About Profits, Not About Safety
Proponents of reimportation believe the issue of drug importation
circles around the profits of pharmaceutical companies, not the safety of
reimported drugs. Over the past few years the U.S. economy has
struggled under a recession with unemployment reaching its highest level
since 1995.89 But one sector of the U.S. economy continues to prosper-
the pharmaceutical industry.90 In 2001, corporate profits sank for the
average Fortune 500 Company, but the pharmaceutical industry (on the
Fortune 500 list) watched as their profits soared by thirty-three percent. 91
While working families are struggling to pay for necessary medicines
and to deal with an increasingly bleak economic picture, the
pharmaceutical industry has continued to prosper.
92
In addition to the pharmaceutical industry's prosperity, the top
executives in this industry were not exactly struggling to make ends
meet. In fact, the top five most highly paid industry executives pocketed
more than $183 million in compensation during the 2001 calendar year.93
This does not even take into account stock options, which can add
millions of dollars to an executive's income.94
While the pharmaceutical industry and its "big-time executives"
rake in Vast sums of money, proponents of reimportation point out that
working families and seniors struggle with the high cost of prescription
drugs. In 2000, about twenty-nine percent of Americans failed to fill a
prescription simply because they were unable to afford to. 95 This is
largely attributable to the fact that the cost of prescription drugs in the
United States has been increasing at a rate of about fourteen percent
89. Hall, supra note 13.
90. Id.
91. Id. The nine largest pharma companies raked in $30.6 billion in 2001. Id. Over
the past decade, drug companies' profits represented an 18.5 percent return on revenue as
opposed to a median return of Fortune 500 companies of 3.3 percent. Id.
92. Id.
93. Id. Additionally, the average compensation for the top twenty-five
pharmaceutical executives was $6 million. Id.
94. Id. For example, in 2000, the chairman and CEO of Bristol-Myers Squibb held
unexercised options valued at $227.9 million. Id.
95. Id.
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annually, sixteen percent from 2000-2001.96 With the aforementioned
prosperity of the drug industry and its executives, are these price
increases really necessary?
Proponents of reimportation would answer this question in the
negative, and then, in addition, point to the price of prescription drugs in
foreign markets. On average, brand-name prescriptions drugs, when
compared to U.S. prices, are fifty-three percent cheaper in Italy, fifty-five
percent cheaper in France, sixty-four percent cheaper in Sweden, sixty-
five percent cheaper in Germany and sixty-nine percent cheaper in the
United Kingdom. 97  It is even more surprising when U.S. prices are
compared to the prices of its close neighbor, Canada, which, on average,
are sixty-two percent less than the U.S. for the exact same prescription
drugs.98 To that end, even though the pharmaceutical industry is thriving
in the American market, American working families and seniors are
burdened with outrageous drug prices while foreign markets are
receiving the benefit of cheaper prescription drugs. 99  Now, when
struggling Americans are trying to use the foreign market to attain
affordable prescription drugs, the pharmaceutical industry say these
drugs are unsafe.
This begs the question-is the drug industry opposing reimportation
of prescription drugs because these drugs are actually unsafe or because
it wants to ensure it can continue to make vast profits from the United
96. Barrios and Festa, supra note 3. Although prescription drug spending in the
United States historically increases about fourteen percent annually, from 2000 to 2001,
prescription drug spending grew sixteen percent. Id.
97. Hall, supra note 13.
98. Id. See also, Hawryluk, supra note 12. This article contains a chart comparing
U.S. prices at Drugstore.com with prices obtained by MedicineAssist, an online service
allowing seniors to order from pharmacies in Canada. Id. Moreover, Dr. Alan Sager of
Boston University has estimated that purchasing U.S. prescription drugs at Canadian
prices would result in a $38.4 billion per year savings. Terry, supra note 10 at 207-08
(citing Hawryluk, supra note 12). A congressional estimate is even more optimistic;
American consumers could save approximately $635 billion per year. Id. (citing
Pharmaceutical Market Access Act of 2003, H.R. 2427, 108th Cong. § 2(5)).
99. To illustrate, both spouses of an elderly American couple have been suffering
from high blood pressure and cholesterol. Connolly, supra note 53, at A02. Since the
couple is unable to afford to purchase a full dose of necessary prescription drugs, the
couple has been taking free samples of Lipitor, which they have received from their
doctor, and splitting it in half. Id. Proponents of reimportation quickly point out that by
utilizing foreign sources, this elderly couple would more likely be able to afford enough
Lipitor to keep both of their high blood pressures under control. Id. Also see Jones supra
note 9. Ray Park, an employee who worked as a train operator for LTV Steel for forty-
one years, lost his health benefits when LTV Steel filed for bankruptcy in late 2000. Id.
Mr. Park is a diabetic who has had open-heart surgery and pays approximately $1,315 a
month for drugs to control his diabetes, cholesterol, and high blood pressure. Id. By
crossing the border to Canada, Mr. Park was able to obtain almost a year's worth of
prescription drugs for only $999. Id.
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States, the one market where the government does not regulate the price
of prescription drugs? Proponents of reimportation argue the latter,
believing that foreign-market drugs pose no larger danger to Americans
than domestically manufactured medications. 00 This argument carries a
lot of weight considering Dr. Peter Rost, vice president of the drug
company Pfizer, publicly criticized his own industry by announcing his
belief that "patented drugs from Europe or Canada may even by safer
than buying drugs in the United States."10 1  For instance, Canada's
equivalent to the FDA, Health Canada, conducts similar regulatory
reviews of drugs to ensure there is "sufficient evidence of safety,
efficiency and quality before they authorize their sale in Canada."' 02
Furthermore, the Canadian health ministry has assured the FDA that all
imported drugs will be equally safe and effective whether they are for
use by Canadians or for export. 10 3  With these assurances of safety,
proponents of reimportation hold firmly to their position that the
pharmaceutical industry is more concerned with profits and less
concerned with safety.
Proponents of reimportation also realize that the pharmaceutical
industry is not alone in its position; the FDA also believes that
reimportation presents a serious safety risk to the health of Americans.1
°4
But, in almost every other sector of the American economy, Americans
are allowed to benefit from the cost savings born of free market
competition, safely. 105 Rather than banning only those prescription drugs
that do not measure up to the FDA standards and making sure
unapproved drugs do not enter into the United States, the FDA spends its
time scaring Americans into compliance with a law that inhibits them
100. See The ChamplainChannel.com, Industry Executive Calls for Drug
Reimportation: Vermont Lawmakers Consider Proposal (Jan. 14, 2005), at
http://www.thechamplainchannel.com/health/4082083/detail.html (last visited Feb. 9,
2005) [hereinafter ChamplainChannel].
101. Id. Dr. Rost further stated, "Others are paid to oppose reimportation and one day
I believe they too will be held responsible, just like the tobacco executives have been.
So, why am I, a drug company executive, standing before you today to speak out? Like
many others in my industry, I joined the pharmaceutical industry to save lives .. " Id.
102. Health Canada, The Regulation of Prescription Drugs: Roles and
Responsibilities (May 2004) available at http://www.hc-sc.gc.ca/english/media/releases/
2004/intemetLpharmacybkl.htm (last visited Feb. 11, 2005). Once in the market, Health
Canada monitors its use for ongoing safety and effectiveness, and continues to ensure that
manufacturers comply with Canada's Regulations. Id.
103. Marc Kaufman, Canada to Guarantee Imported Medicine, THE WASHINGTON
POST, May 8, 2003, at A06.
104. Turner, supra note 43, at 8.
105. Barrios and Festa, supra note 3. Whether it is a kiwi from New Zealand or a Kia
automobile from South Korea, federal law has always allowed Americans to participate
in free market competition. Id.
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from participating in the free market. 10 6 If the FDA is worried about
unsafe drugs entering into the United States, it should set up a regulatory
system that allows the FDA to review and license companies seeking to
import prescription drugs from Canada.10 7 This would ensure the FDA
one hundred percent compliance with federal law, while still providing a
route to safe purchases of cost-saving drugs.'
0 8
Proponents of reimportation want American lawmakers to realize
that safety should not be the only issue surrounding the importation of
prescription drugs; they must concentrate on the profits of the
pharmaceutical industry. Although the pharmaceutical industry has a
right to use the American market to maximize its profits, it must realize
that American working families and seniors also have a right, pursuant to
free market competition, to pursue cheaper prescription drugs in foreign
countries. The industry's safety argument is quashed, considering Health
Canada has similar regulations. If the pharmaceutical industry chooses
to sell drugs to foreign countries at cheaper prices, then it should suffer
the consequences-not hide behind the fallacy issue of safety.
2. Research and Development Costs and the Costs of Advertising
The pharmaceutical industry and critics of reimportation argue that
higher prices for prescription drugs are necessary for the research and
development that has made the United States the global engine for
pharmaceutical innovation.10 9 Proponents of reimportation attack this
argument on several grounds: First, the pharmaceutical industry is
simply playing a research and development "Scare Card" because it
actually does not spend as much on research and development as it
claims; second, even assuming, arguendo, that the pharmaceutical
industry is spending as much as it says it is on research and development,
the burden should not be placed entirely on U.S. citizens; and finally, if
research and development is so important, then why does the industry
spend a considerable amount more on advertising?
106. Id. This is even assuming, arguendo, that prescription drugs from foreign
markets are unsafe. The vice president of Pfizer, a senior executive of a major drug
company, stated that he believed foreign-made drugs pose no larger danger to Americans
than domestically manufactured medications; "however painful it is for me to say this, I
think patented drugs from Europe or Canada may even be safer than buying drugs in the
U.S." ChamplainChannel, supra note 100.
107. Id. The authors of this article believe that this is the best solution to the debate
on drug importation.
108. Id.
109. Kaufman, supra note 44, at All.
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a. The Pharmaceutical Industry's R&D "Scare Card"
The drug industry claims that, on average, the research and
development costs for a new drug is approximately $500 million.110 The
industry argues that if anything is done to moderate prices or profits in
the United States, then research and development will suffer and "it's
going to harm millions of Americans who have life-threatening
conditions." ' In other words, the high prescription drug prices allow
for continued research and development funding, and any decrease in
pricing would eventually result in decreasing research and development,
which would finally harm the end consumer."
12
Proponents of reimportation understand this argument, but believe
the $500 million cost for researching and developing a new drug is
heavily inflated. 13 Proponents argue that the actual costs of research and
development are inflated because they fail to account for public
contributions, tax credits, and other sources of contributions that actually
decrease the final cost to the pharmaceutical companies.' 14 In support,
proponents of reimportation simply point to Pharmaceutical Research
and Manufacturers of America's own assertions: during the 1990's, drug
companies spent $139.8 billion on research and development; during this
same period, the FDA approved 857 new drugs; after simple division,
this suggests that only $163 million was spent on research and
development of a single new drug in the 1990's.115  Moreover, this
110. Public Citizen, Rx R&D Myths: The Case Against the Drug Industry's R&D
'Scare Card,' at http://www.citizen.org/ publications/release.cfm?ID=7065 (last visited
Feb. 12, 2005) [hereinafter Public Citizen]. A 2003 study conducted by the Tufts Center
for the Study of Drug Development concluded that it costs $897 million to develop a new
prescription drug. Tinsley, supra note 30, at 443 (citing The Tufts Center for the Study
of Drug Development, News Release: Total Cost to Develop a New Prescription Drug,
Including Cost Of Post-Approval Research, is $897 million, at http://csdd.tufts.edu/
NewsEvents/RecentNews.asp?newsid=29 (last visited Mar. 6, 2004)). These studies,
however, have been heavily criticized for being inflated. Id. at 444.
111. Public Citizen, supra note 110. Pharmaceutical Research and Manufacturers of
America's (PhRMA) president made this statement in defending the high price of
prescription drugs in the U.S. Id.
112. Tinsley, supra note 30, at 446 (citing Michele L. Creech, Comment, Make a Run
for the Border: Why the United States Govn 't is Looking to the International Market for
Affordable Prescription Drugs, 15 EMORY INT'L L. REv. 593, 600 (2001)).
113. Public Citizen, supra note 110. It is important to note that Public Citizen only
used domestic expenditures in its analysis, assuming that foreign expenditures of U.S.-
owed firms will be directed primarily to non-U.S. introductions. Id.
114. Tinsley, supra note 30, at 444 (citing Public Citizen, supra note 113). In
addition, federal funding makes up nearly half of the total amount spent on health care
research and development. Id. at 446 (citing Michael B. Moore, "Open Wide" (Your
Pocketbook That Is)-A Call for the Establishment in the United States of a Prescription
Drug Price Regulatory Agency, I Sw. J. L. & TRADE AM. 149, 156 (Fall 1994)).
115. Public Citizen, supra note 110.
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number could be significantly lower if further analysis is undertaken.
For instance, the $139.8 billion total spent on research and development
is a pre-tax figure; in fact, research and development expenses are tax
deductible and every dollar spent on research and development has a net
cost of only $0.66. 116
To that end, the proponents of reimportation believe the
pharmaceutical industry is playing a "Scare Card" with the issue of
research and development costs. In actuality, the generous estimation of
$163 million to research and develop a new drug is a significant number,
but it is no where near the $500 million cost claimed by the drug
industry. Instead of claiming the total amount it costs to introduce a new
drug, the pharmaceutical industry should simply reveal its actual cash
outlay for the new drug-it should not include public contributions, tax
benefits and any other contributions that inflate its actual cost for
research and development.
b. Only the U.S. is Burdened
Even assuming, arguendo, that research and development costs are
equal to $500 million per new drug, why are Americans the only ones
bearing the burden of paying for research and development of new
innovations-when the entire world is reaping the benefits?
It is most likely because the United States is the only industrialized
nation that does not have government set price controls on prescription
drugs." 7 FDA Commissioner Mark McClellan has argued that countries
regulating drug prices do not pay their fair share of the research and
development costs-they depend on the United States to pick up the
slack. 8  In Canada, the Patented Medicine Prices Review Board
(PMPRB)" 9 dictates the maximum price for a new prescription drug
entering the Canadian market by ensuring the prices of Canadian
pharmaceuticals are no higher than a product's mean price in seven
industrialized nations. 20  In setting a drug's price, the PMPRB can
116. Id.
117. Harris, supra note 25. Approximately half of the pharmaceutical industry's
profits come from the United States. Id.
118. Tamsin Carlisle, Pfizer Pressures Canadian Sellers of Drugs to U.S., WALL ST.
J., Jan. 14, 2004. The large pharmaceutical companies and the FDA believe that the rest
of the world needs to contribute in the research and development of new prescription
drugs. Id.
119. Patented Medicine Prices Review Board, Home Page, available at
http://www.pmprb-cepmb.gc.ca/english/ home.asp?x=l (last visited Feb. 15, 2005).
120. Mary E. Wiktorowicz, Emergent Patterns In The Regulation Of
Pharmaceuticals: Institutions And Interests In The United States, Canada, Britain, And
France, 28 J. HEALTH POL. POL'Y & L. 615, 627 (2003). In setting and limiting prices,
the PMPRB considers the drug's Canadian price, the price in other markets, the price of
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consider manufacturing and marketing costs, but it cannot take the cost
of research and development into its calculations.12 1 Similarly, each
European nation has instituted its own price control system, many of
which coincide with each other.12 2 These price control systems have
prevented innovative pharmaceutical firms from reaping infinite profits
anywhere but in the United States. 1
23
This has also forced many of the traditional European firms, such as
GlaxoSmithKline and Novartis, to move many of their most essential
operations to the United States where more money can be spent on
research and development.12 4 While this relocation has given American
manufacturers the ability to account for seven of the top ten worldwide
best-selling medicines, it also reflects a large and growing disparity in
research and development expenditures. 2 5  In 2000, United States
manufacturing firms outspent European firms on research and
development by approximately $6.1 billion.126  This is a remarkable
turnaround considering that ten years ago, before such stringent
government price controls were in effect, 1 7 European pharmaceutical
firms outspent American firms on research and development by
approximately $2.7 billion.
This large, disproportionate research and development expenditure
is causing unrest in the United States. 128  "The United States is now
similar medicines within Canada, Canada's Consumer Price Index, and the cost of
making and marketing the drug. See Farin Khosravi, Comment, Price Discrimination In
The United States: Why Are Pharmaceuticals Cheaper In Canada And Are Americans
Seizing The Opportunities Across The Border?, 9 SPG L. & Bus. REV. AM. 427, 433
(2003). If the PMPRB determines that the price of a drug is too high, it can induce the
manufacturer to voluntarily reduce the price; hold a public hearing and either order the
maker to reduce the price or take away its market exclusivity; or require the patent owner
to reduce the price of another drug or remit money to the government. Id.
121. Todd A. Rosenfield, Comment, The Counterfeit Drug Invasion: How Drug
Reimportation Unjustifiably Poses A Threat To The Health Of The U.S. Public, 25 U. PA.
J. INT'L ECON. L. 1047, 1053 (2004).
122. Id. For example, the Netherlands takes into account the average price of
prescription drugs in Belgium, France, Germany, and the United Kingdom in setting its
price. Id. Another example is Portugal, which demands the lowest price set in France,
Italy, or Spain. Greece wants the lowest price in all of Europe, period. Id.
123. Id. This is one of the reasons why the world pharmaceutical industry, which
twenty years ago was primarily based in Europe, has largely relocated to the United
States.
124. Id.
125. Id. American manufactures also account for fifteen of the top twenty best-
selling medicines.
126. Id.
127. Id. The European Commission is sufficiently alarmed by these trends and is
proposing measures to relax price controls in order to rejuvenate its pharmaceutical
industry.
128. Elizabeth Becker, Overseas drug prices targeted by industry U.S. officials
pressure Australia on controls, THE SAN DIEGO UNION-TRIBUNE, Nov. 27, 2003. This
[Vol. 23:4
To THE U.S. GOVERNMENT
covering most of the costs of developing a new drug to the point where it
can be used by the population of the world," 129 according to FDA
commissioner Mark McClellan. "It is clear to me [Mr. McClellan] that
we cannot carry the lion's share of this burden for much longer."' 130 The
benefits of United States drug innovations are global, and the cost for
researching and developing these drugs should be global as well.
131
By the United States allowing reimportation or even dropping its
drug cost to the average of the rest of the world, it may be able to compel
each foreign country to take on their respective share of the cost of
researching and developing new prescription drugs.' 32  Proponents of
reimportation believe this drop in sales would prompt the pharmaceutical
industry to negotiate higher price regulation with foreign countries,
which, in turn, will spread out the cost of research and development. 1
33
c. Advertising/Lobbying Expenses are Too High
The pharmaceutical industry has adamantly stressed its position that
higher prescription drug prices are necessary to fund research and
development of new innovative drugs. The question, however, is how
much of the costs are actually being allocated to research and
development, as opposed to advertising, marketing, lobbying, and public
relations?
The answer to this question can be ascertained by evaluating how
drug manufacturers spend their revenues. Take a look at the cost
breakdown of Lipitor, one of the most popular and highly prescribed
drugs for high cholesterol. 134 Twenty-four percent of the cost of Lipitor
is pure (net) profit, twenty-six percent covers "other expenses,"'135 thirty-
article explains how the United States is asking other countries, such as Australia, to
agree to pay higher prices for new drug innovations. Id.
129. Id. Mark McClellan made this statement in denouncement of other countries
who are allowing the United States to bear the burden of developing new drug
innovations. -d.
130. Id.
131. Id. This idea comes from a speech made in September by FDA commissioner
Mark McClellan. Id.
132. Julie Appleby, More cities, states opt for Canadian drugs; FDA might be forced
to challenge each program, USA TODAY, Dec. 23, 2003, available at
http://www. usatoday.com/money/industries/health/drugs/2003-12-23-canadadrugs-,x.htm
(last visited Feb. 7, 2005).
133. Id. Tony Howard, the chief executive at CanaRx, stated that "If the United
States were to drop costs to the average of the world, and then the pharmaceutical
industry said it needed more money for research and development, then it could add a
dollar to every prescription filled throughout the world." Id. Compare discussion supra
Part I.B.2.
134. Hall, supra note 13.
135. Such as manufacturing, executive pay, worker costs, etc.
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five percent covers advertising and marketing and only fifteen percent
covers the cost or research and development. 136 These percentages alone
showcase that pharmaceutical companies, on average, spend more to
advertise their drugs then they do to research and develop their drugs.
This begs the question-why do the pharmaceutical companies blame
the high cost of prescription drug prices on research and development
and not on advertising when they are spending approximately eight
percent more on advertising?
The answer may be that the pharmaceutical industry realizes that
Americans will be more sympathetic to higher prescription drug prices if
the high prices are attributable to the research and development costs
associated with the drug and not the drugs' advertising costs. Americans
have to see through these self-serving scare tactics and realize that the
drug industry is driven by profit.137 The pharmaceutical industry does
not want to limit its advertising expenses because it knows advertising its
products to consumers stimulates extensive profits.
To put this further in perspective, $2.5 billion was spent on
promoting prescription drugs directly to consumers in 2000.138
Television advertising, which is the largest and fastest growing type of
direct-to-consumer advertising, has grown from thirteen percent in 1994
to sixty-four percent in 2000.139 While this is less then the amount
automobile companies spend on advertising, it is comparable to the
amount expended by the motion picture industry and the "computer-
maker" industry.1 40 Promoting drugs directly to consumers has proved
so extremely profitable that some pharmaceutical companies invest more
money in such promotions than they budget for informing physicians
about their products. 1
41
136. Hall, supra note 13.
137. Congressman Sherrod Brown, Brown Blasts Drug Industry Ads, (July 15, 2003)
available at http://www.house.gov/sherrodbrown/drugads7l503.html. Congressman
Brown denounced the latest round of misleading ads from the pharmaceutical companies.
Id.
138. The Henry J. Kaiser Family Foundation, Direct-to-Consumer Prescription Drug
Advertising, (Jan. 18, 2004), available at http://www.kaisernetwork.org/adwatch/
adwatchindex.cfm?display=detail&aw=285 (last visited Feb. 15, 2005). This was an
increase of almost thirty-five percent over spending in 1999. Id.
139. Id. This represents an eighty-eight percent average annual increase in television
advertising spending from 1994-2000. Id.
140. Jones, supra note 8. The article has the advertising figures, compiled by TNS
Media Intelligence/CMR, of the prescription drug industry, the automobile industry, and
the computer-maker industry. These figures are for the 2002 year and the midway point
of the 2003 year. Id.
141. The American Council on Science and Health, Inc., Does Direct-to-Consumer
Prescription Drug Advertising benefit the Public's Health? (1999) (Issue and answer
from Dr. Phillip R. Alper), available at http://www.acsh.org/publications/
priorities/1 104/point.no.html (last visited Jan. 5, 2004).
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These astounding advertising statistics do not even take into account
the amount of money the pharmaceutical industry expends on lobbying.
In the 2000 presidential election, the pharmaceutical industry made more
than $20 million in political expenditures.142  Since the election, the
industry has contributed $60 million in political donations and spent
approximately $38 million in lobbying in the first six months of this
year. 43 Furthermore, the drug industry has set aside at least $150 million
dollars to spend in 2004.144 All of these expenses, which add to the high
price of prescription drugs in the United States, are aimed at influencing
American thought on prescription drugs-making Americans believe
that the high prices are attributable to researching and developing new
drug innovations. In reality, according to the proponents of
reimportation, the drug industry uses its money and power to keep its
grip on the lucrative United States prescription drug market. 1
45
Instead of stressing its position that higher prescription drug prices
are necessary to fund research and development, the proponents of
reimportation believe that the pharmaceutical industry should limit these
outrageous advertising and lobbying expenses. If the $2.5 billion spent
on advertising and the $150 million set aside to lobby were used to
reduce the price of prescription drugs, the need of Americans to reimport
prescription drugs from foreign countries would be eliminated. 146 At the
same time, the amount of money that goes into researching and
developing newer drugs would not be affected. Until the drug industry
pursues this course of action, it should not blame the high price of
prescription drugs on the research and development of new
innovations. 1
47
142. David Espo, Lobbying Strong vs. Prescriptions Bill, THE MIAMI HERALD, July
24, 2003, available at http://www.miami. com/mld/miamiherald/63 72599.htm (last visited
Feb. 15, 2005). Of the twenty million in political contributions by the pharmaceutical
industry, roughly eight out of every ten dollars went to the Republicans. Id.
143. Ceci Connolly, Drugmakers Protect Their Turf, THE WASHINGTON POST, Nov.
21, 2003, at A04. The massive political contributions and lobbying was undertaken to
keep reimportation illegal and to urge the passage of the new Medicare bill that adds
prescription drug coverage to Medicare recipients. Id.
144. Congressman Sherrod Brown, supra note 137. Congressman Brown stated that
the drug industry has set aside at least $150 million for 2004 to influence American
though on prescription drugs. Id.
145. Id.
146. The author assumes these savings on advertising and lobbying would be passed
onto the consumer, thereby reducing the price Americans pay for their prescription drugs.
147. While the author realizes that advertising directly to consumers may help people
by giving them a means to ask questions about their health, he takes the position that the
pharmaceutical industry goes above and beyond that necessary to inform the public. For
instance, it really is not necessary for pharmaceutical companies to hire famous
spokesman, such as baseball player Raphael Palmeiro, simply to market a drug. See
Mike Huckman, Arch Rivals: Glaxo vs. Phizer, CNBC looks at the battle between top
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II. State Action
Certain states agree with the FDA and have taken action against the
storefront distributors and Internet pharmacies promoting reimportation
within their respective state.148 A growing number of states, however,
are taking the position that drug reimportation should be legalized
because it is a safe, effective means of cutting the states' healthcare
Costs. 149 In fact, many of those states that were adamantly against drug
reimportation have changed their tune and are now attempting to
establish programs to sell prescription drugs reimported from Canada.
150
The following subsections will provide a brief overview of the specific
actions states have taken on this complicated issue of drug
reimportation. 151
A. States Against Importation
The states that support the position of the FDA have taken the
stance that the importation of prescription drugs is not only unsafe, but it
is also illegal. 52 The first state to take official action against a storefront
distributor was Oklahoma, which filed a complaint in the District Court
of Oklahoma County on March 27, 2003.15' The complaint asked the
industry brands, Dec. 16, 2003, available at http://msnbc.msn.com/id/3721062 (last
visited Feb. 15, 2005). The author firmly believes that important health information can
be passed on without the expenditure of paying a sports star.
148. National Association of Chain Drug Stores (NACDS), FDA Actions and
Positions, available at http://www.nacds.org/wmspage.cfm?parml=2935 (last visited
Feb. 15, 2005) [hereinafter NACDS]. The NACDS set up a Web page dedicated to drug
importation. Id. It lists all of the actions states have taken against drug importation. Id.
149. Appleby, supra note 132. A growing number of cities, counties and states have
stated that they want to allow employees, retirees and ordinary citizens to purchase
prescription drugs from Canada. Id.
150. For instance, Oklahoma filed a complaint in the District Court of Oklahoma
County on March 27, 2003 asking the District Court to enjoin a storefront distributor, Rx
Depot, from violating the Oklahoma Pharmacy Act. The Oklahoma State Bd. of
Pharmacy v. Rx Depot, No. CJ-2003-2643 (District of Oklahoma County filed March 27,
2003), available at http://www.nacds.org/user-assets/PDFfiles/OklahomaBOP
Complaint.pdf (last visited February 3, 2005). More recently, Oklahoma is considering
the establishment of "Rx for Oklahoma," which is a program that would provide a
website allowing Oklahoma citizens to order cheaper prescription drugs from Canada and
other industrialized countries. Carol Cole, Steele, Hiett Introduce 'Rx for Oklahoma,'
SHAWNEE NEWS-STAR, February 2, 2005, available at http://www.news-star.com/
stories/020205/New_26.shtml (last visited February 14, 2005).
151. The states for and against reimportation refer to the same arguments that were
extensively discussed in Part I of this Comment. This section of the Comment will
simply discuss the specific actions taken by certain states.
152. While this subsection discusses certain state actions in opposition of
reimportation, it is by no means exhaustive. For a more comprehensive discussion of
State action taken against reimportation, see NACDS, supra note 148.
153. The Oklahoma State Bd. of Pharmacy v. Rx Depot, No. CJ-2003-2643 (District
[Vol, 23:4
To THE U.S. GOVERNMENT
District Court to enjoin a storefront distributor, Rx Depot, from violating
the Oklahoma Pharmacy Act. 154 The Alabama 15' and North Carolina
56
Board of Pharmacy's filed similar complaints against storefront
distributors in their respective states.
Other states have chosen to pursue other options in attempting to
eliminate the storefront distributors residing within their jurisdiction.1 57
For example, the Arizona Board of Pharmacy issued a letter to the
Arizona Better Business Bureau asking it to warn consumers about the
risks of purchasing prescription drugs from Canada. 158  The Arizona
Board stressed its position that storefront distributors violate state and
federal law.159  Similarly, Oregon's Board of Pharmacy issued a
statement regarding the illegality and danger of storefront distributors.
60
Both the Arizona and the Oregon Boards of Pharmacy stressed the need
for consumers to contact their doctors or pharmacists for safe, cost-
effective alternatives to drug importation.
16
Kansas Attorney General, Phill Kline, sent a letter to Rx Depot, a
storefront distributor, ordering it to cease operations because it exhibits
the "Rx" symbol, which is an explicit violation of Kansas law. 162 The
letter gave Rx Depot fifteen days to comply before it would face further
of Oklahoma County filed March 27, 2003), available at http://www.nacds.org/user-
assets/PDFfiles/ OklahomaBOPComplaint.pdf (last visited Feb. 3, 2005).
154. Id. The Oklahoma Pharmacy Act is codified in 59 O.S.Supp.2002, Section 353
et seq.
155. Alabama State Bd. of Pharmacy v. Disc. Drugs of Canada, No CV 03-1742
(Circuit Court of Jefferson County Filed March 31, 2003), available at
http://www.nacds.org/user-assets/PDF files/ALBOP_.Complaint.pdf (last visited Feb. 3,
2005). The defendants consented to the Court issuing a Temporary Restraining Order to
remain in full force until the hearing on the Plaintiffs request for a preliminary
injunction.
156. North Carolina Bd. of Pharmacy v. Canada Drug Outlet, Inc., No. 3 CVS04986
(N.C. Superior Court Division filed Oct. 15, 2003), available at http://www.nacds.org/
user-assets/PDFfiles/NC_BOP_vCanada.pdf (last visited Feb. 3, 2005).
157. NACDS, supra note 148.
158. Arizona Board of Pharmacy Urges Better Business Bureau to Warn Consumers
About Prescription Drugs From Canada: You Can't Trust the Source; Letter Cites
Repeat Felon Operating Canadian Drug Import Service, PR Newswire, May 9, 2003,
available at http://www.findarticles.com/cf dls/m4PRN/2003 May_9/l014881 24 /pl/
article.jhtml?term= (last visited Jan. 4, 2004). This article describes the actual letter sent
by the Arizona Board of Pharmacy. Id.
159. Id.
160. Gary A. Schnabel, Statement regarding Oregon storefront businesses that solicit
drug therapy patients to hand over prescriptions to be filled in Canada, Oregon Board of
Pharmacy, Oct. 17, 2003, available at http ://www.nacds.org/user-assets/
Wordfiles/ORStatement_ Storefronts.DOC (last visited Feb. 3, 2005).
161. Id.
162. Theresa Agovino, Rx Depot ordered to close stores, THE KANSAS CITY STAR,
Sept. 10, 2003, available at http://www.kathrynpetro.com/mindfullife/archives/
000035.html (last visited Feb. 3, 2005).
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action by the Attorney General or the Kansas Board of Pharmacy.
163
Lastly, in March of 2003, the Montana Board of Pharmacy sent
Club Medzrx a letter ordering it to cease and desist its operations, as their
practice of assisting Montana residents in obtaining drugs from RealFast
Drugstore in Canada violates a number of state laws and regulations
addressing appropriate licensure, advertising and use of pharmacy
technicians. 1
64
B. States for Importation
A growing number of cities and states have been exploring ways to
permit their residents to benefit from the cheaper prescription drugs
existing in Canada. 165 A chief executive of CanaRx, 166 Tony Howard,
actually stated that CanaRx was negotiating with approximately sixty
cities and counties within the United States about instituting prescription
drug importation programs. 167 One of the first cities to actually institute
a program was Springfield, Massachusetts. 168  Its mayor, Michael J.
Albano, has set up a voluntary Canadian mail-order option for city
workers and retirees that he believes could cut the city's $18 million
annual prescription drug bill in half.169  Mayor Albano believes so
strongly in the safeness of the program that he uses it to purchase the
prescription drugs he needs for his diabetic son.
170
The city of Montgomery, Alabama was actually the first city to
institute a prescription drug importation program with Canada.
171
163. Id.
164. Letter from Montana Board of Pharmacy to Club Medzrx, at
http://www.nacds.org/user-assets/PDF-files/ClubMedz_CeaseDesistMT.pdf (last
visited Oct. 26, 2005).
165. Associated Press, 10 States seek prescriptions from Canada, ST. PETERSBURG
TIMES (Florida), Dec. 12, 2003, available at http://www.sptimes.com/2003/12/12/
news.pf/Worldandnation/10 states_seekprescr.shtml (last visited Feb. 3, 2005).
Specifically, this article enumerates ten states that are exploring ways to buy cheap
prescription drugs from Canada.
166. CanaRx is a Canadian pharmacy that sends prescription drugs into the United
States. It currently provides prescription drugs for the city of Springfield's program.
167. Appleby, supra note 132.
168. MacDonald, supra note 11.
169. Id. The system set up by Mayor Albano allows city workers and retirees to
choose whether they would like to order their drugs from Canada. It is a completely
voluntary system. Id.
170. Trudy Tynan, Mass. City Buying Drugs From Canada, THE WASHINGTON POST,
July 29, 2003, available at http://www.seacoastonline.com/2003news/07292003/
south_of/42139.htm (last visited Feb. 3, 2005). Mayor Albano stated that he has
purchased the prescription drugs for his diabetic son through Springfield's program and
has, in turn, saved $853 a year for the city. Id.
171. Appleby, supra note 132. Many people believe that Springfield, Massachusetts
was the first to institute an importation program, but this is only because Montgomery,
Alabama chose to keep its program quiet. Id.
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Montgomery's program allows city employees and retirees to choose
whether they want to purchase their prescription drugs from Canada.
172
Those employees who decide to opt for the program essentially receive
their prescription drugs for free because the city has saved so much
money that it has dropped its fifteen percent co-payment.173  The
program, which started in December of 2002, has saved Montgomery
approximately $400,000-$500,000 in the first year.
1 74
Minnesota governor, Tim Pawlenty, announced a five-phase plan
that would allow its state residents to purchase prescription drugs from
approved Canadian pharmacies. 175  Under the first phase, which is
already underway, Minnesota established a Web site which allows its
residents to gather information about prescription drug purchases, view a
list of Minnesota-approved pharmacies, compare prescription drug
prices, and learn about cost saving strategies. 176  To actually order
prescription drugs, Minnesota residents simply must locate their
medicine on the website, send it to a listed pharmacy (Canadian), and
wait for the pharmacy to fill the prescription. 177 This innovative plan
allows Minnesota to help its residents passively-this way the state is not
a direct importer of drugs in violation of federal law.
178
Illinois governor Rod Blagojevich has been very active in pursuing
affordable prescription drugs for Illinois residents. In October of 2003,
Governor Blagojevich issued a report finding that Illinois residents could
safely purchase drugs from Canada because the pharmacy practice in the
Canadian provinces of Manitoba and Ontario is equal to or superior to
the pharmacy practices in the State of Illinois. 179  The report further
found that buying prescription drugs from Canada could save the State of
172. Id.
173. Id. The elimination of the co-payment applies only to those employees that opt
for the reimportation program.
174. Id.
175. Tom Majeski, Governor's Rx; Import drugs, ST. PAUL PIONEER PRESS
(Minnesota), Oct. 17, 2003, available at http://www.twincities.com/mld/
pioneerpress/news/politics/703239 9 .htm (last visited Feb. 3, 2005). The plan, however,
was narrowed and now includes only three major phases. Tinsley, supra note 30, at 468.
176. Id. The program also provides for residents that do not have Internet access by
allowing them to order prescription drugs by phone. Majeski, supra note 175.
177. Tinsley, supra note 30, at 470-71. The website does not allow direct purchases
because this practice has already been ruled illegal in U.S. v. Rx Depot. Id. at 471.
178. At least three other states-New Hampshire, North Dakota and Wisconsin-
have also established Web sites to help residents purchase prescription drugs from
Canada. Monica Davey, Illinois To Help Residents Buy Drugs From Canada, and Afar,
N.Y. TIMES, Aug. 17, 2004, at A2 1.
179. "Report of Feasibility of Employees and Retirees Safely And Effectively
Purchasing Prescription Drugs From Canadian Pharmacies" available at
http://www.affordabledrugs.il.gov/pdf/SpecialAdvocateCanadianl O-27-O3Final.pdf (last
visited Oct. 26, 2005).
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Illinois $55 million annually.' 80
In January of 2004, Governor Blagojevich started the "Illinois Rx
Buying Club,"' 81 which allows the state to use its buying power to
negotiate lower prices from domestic drug manufacturers.' 82  The
purpose of the program is to solicit enough members to create a
substantial buying power that enables the group to negotiate lower prices
with pharmaceutical companies. 83  While this program has solicited
about 74,400 participants, it has not reached its goal of 1.5 million
participants. 84 Thus, the "Buying Club" has not been able to negotiate
as strongly as it first anticipated.
185
Lastly, Governor Blagojevich, in mid-August of 2004, announced
his intention to set up a program giving Illinois residents the ability to
purchase prescription drugs from Canada, England, and Ireland. 86 The
program allows Illinois residents to use a Web Site or a toll-free number
to purchase about 100 products the state has determined can be safely
shipped from outside the U.S.'87 Illinois residents simply need to enroll
and submit a valid prescription and an in-state mailing address to enjoy
twenty-five to fifty percent savings when compared to U.S. retail
prices.188
Vermont has decided to take a different route in making prescription
drugs more affordable to its residents, becoming the first state to actually
180. Id. at pg 3-4.
181. This program allows Illinois residents, older than age 65 or with disabilities, to
save an average twenty percent off the price of prescription drugs. Daily Health Policy
Report, Prescription Drugs: Illinois To Launch Program To Reimport Prescription
Drugs From Canada, England and Ireland, Despite Warning from FDA, Aug. 17, 2004,
available at http://www.kaisernetwork.org/daily-reports/rep-index.cftn?hint=
3&DR ID=25297 (last visited Feb. 14, 2005) [hereinafter Daily Health Policy Report].
182. Id.
183. Tinsley, supra note 30, at 467. The program hopes to obtain enough participants
to go to domestic pharmaceutical companies and say, "If you'll provide a substantial
discount on your products, we can deliver millions of Illinois customers through our state
buying club. And if you refuse to give us all a good break on the price, we'll take our
business to your competitors." Id.
184. Daily Health Policy Report, supra note 181.
185. Id.
186. Julie Appleby, Illinois First to Help Buy Drugs Abroad, USA TODAY, Aug. 17,
2004, available at http://www.usatoday.con/money/industries/health/drugs/2004-08-17-
drugsx.htm (last visited Feb. 14, 2005). Illinois is the first state to help its residents
obtain prescription drugs from Europe. Id. Governor Blagojevich included European
countries in the program to preempt any attempt by the drug companies to shut off
supplies to Canada-believing that the drug companies cannot shut down supplies to the
world only to keep prices high in the United States. Davey, supra note 178, at A2 1.
187. Id. The foreign pharmacies are inspected by state officials to help ensure safety.
Id.
188. Id. The article includes a table that showcases the savings Illinois residents can
expect when purchasing their prescription drugs through this program. Id.
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sue the FDA to be able to import prescription drugs from Canada. 8 9 In
November of 2003 Vermont officials asked the FDA to approve a pilot
program under which the state would contract with a Canadian company
that would take orders from Vermont residents and distribute the drugs
by mail. 190  After receiving a letter denying the request, Vermont
officials sued the FDA believing the FDA's denial to be
"unsubstantiated" and in violation of the Administrative Procedure
Act.' 9' Vermont's proposal would initially allow current and retired state
employees and their dependents to import Canadian drugs, with the goal
of expanding the plan to cover other Vermonters. 192  Although the
Vermont proposal called specifically for the FDA to work with Vermont
to ensure safety, the FDA denied the request stating that "it would be
extremely unlikely that the State of Vermont could ensure that all the
Canadian drugs would be in full compliance with all laws and
regulations applicable to the FDA."' 
93
Many other states have also announced that they are considering
state instituted drug reimportation programs with Canada. These states
include California,' 94 West Virginia,' 95 Delaware, 96 Louisiana,'97 and
North Dakota.
98
189. A Chicago-area couple sued the FDA and the U.S. Department of health and
human Services to permit the legalized import of prescription drugs from Canada, but
Vermont is the first state to take action against the FDA. See Valerie Jablow, Consumers,
States Challenge Federal Ban on Drug Imports, NEWS AND TREND, June 2004, at 40-JUN
Trial 12 (citing Andrews v. Dep't of Health & Human Servs., No. 1:04CV00307 (D.D.C.
filed Feb. 26, 2004)).
190. Pam Belluck, Vermont Will Sue U.S. for the Right to Import Drugs, N.Y. TIMES,
Aug. 11, 2004, at A13.
191. Statement on Vermont's Lawsuit on Importing Prescription Drugs From Canada,
Aug. 20, 2004 http://www.fda.gov/bbs/topics/news/2004/NEW01107.html. The State of
Vermont filed its complaint in the United States District Court for the District of
Vermont. Id.
192. Belluck, supra note 190, at A 13.
193. Id.
194. Jennifer Coleman, California Legislature Eyes Meds From Canada, THE
WASHINGTON POST, Jan. 22, 2004. A bill introduced on January 22, 2003 by Senate
President Pro Tempore John Burton would allow the state Department of General
Services to consider Canadian pharmacies when seeking the best price for prescription
medicines. Id.
195. Associated Press, supra note 165. Mr. Tom Susman, the acting administration
secretary for West Virginia was quoted as saying, "Drugs are cheaper in Canada-how
do we bring these drugs into the states. If they work better, and the cost is cheaper, I
think it's legitimate." Id.
196. Id.
197. Id.
198. Mary Judice, Kenner store defies order to close; Shop still brokering Canadian
Drugs, TIME-PICAYUNE (Louisiana), Nov. 8, 2003. Mayor Michael Bloomberg also
stated that he will press federal officials to allow New York City to import drugs for city
workers. Id.
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III. FDA Action
On March, 21, 2003, the Food and Drug Administration (FDA) sent
Rx Depot, an entity responsible for the creation of approximately eighty-
five storefront distributors, a warning letter informing Rx Depot that its
actions "present a significant risk to public heath" and "mislead the
public about the safety of the drugs" it provides. 199 Despite the warning,
Rx Depot announced its intention to continue to provide access to
Canadian drugs until ordered by a court to stop.200 The FDA, believing
the continued operation of storefront distributors to create a significant
potential health risk, filed a complaint in the United States District Court
in the Northern District of Oklahoma. 20 1 The complaint seeks to enjoin
Rx Depot and individual officers from directly or indirectly importing or
causing the importation of U.S.-manufactured and unapproved foreign-
manufactured prescription drugs into the U.S.20 2  The following will
extensively analyze the court's analysis in deciding on the FDA's request
for an injunction.
A. United States v. Rx Depot
3
United States v. Rx Depot arises from a complaint filed by the
Department of Justice 20 4 asking the court to enjoin the two storefront
distributors, Rx Depot2°5 and Rx Canada, 20 6 because they violate the
Federal Food, Drug, and Cosmetic Act (FDCA), 21 U.S.C. Sections
331(d)20 7 and (t). 20 8  The court ultimately granted the Department of
Justice's motion for preliminary injunction against Rx Depot finding the
storefront distributors in violation of the FDCA because they created "an
unacceptable risk that counterfeit, adulterated, misbranded, subpotent, or
199. FDA News, FDA Takes Action Against Companies That Are Importing
Unapproved, Potentially Unsafe Drugs, Sept. 9, 2003, available at http://www.fda.gov/
bbs/topics/NEWS/ 2003/NEW00939.html (last visited Feb. 15, 2005).
200. Id.
201. Id.
202. Id.
203. United States v. Rx Depot, 290 F.Supp.2d 1238 (N.D.Okla. 2003).
204. Id. at 1240. The Department of Justice filed this complaint on behalf of the
FDA. Id.
205. Id. The Court consistently used "Rx Depot" in its analysis. Id. This was
understood to also include Rx Canada and the other individual defendants Carl Moore
and David Peoples. The same will be done for purposes of this Comment.
206. Id. at 1240-41.
207. Id. at 1245-46. The Department of Justice believes that 21 U.S.C. Section
331(d) is violated each time Rx Depot causes to be introduced or delivered for
introduction into interstate commerce unapproved new drugs. Id.
208. Id. The Department of Justice believes that Rx Depot violates 21 U.S.C. Section
331(t) each time it causes the importation of prescription drugs because only the
manufacturer of a drug can reimport that drug into the United States. Id.
[Vol. 23:4
To THE U.S. GOVERNMENT
expired drugs will be sold to American consumers., 20 9 While granting
the Department of Justice's claims, the court dismissed the five counter-
claims of Rx Depot.210
On the issue of safety, the court sided with the Department of
Justice's argument 21' that prescription drugs imported from Canada are
209. Id. at 1248. To reach this finding the court had to evaluate the following four
factors: 1) the movant has a substantial likelihood of success on the merits, 2) irreparable
injury will occur if the injunction is not granted, 3) the injury that will occur outweighs
any harm the injunction will cause the opposing party, and 4) the injunction is not
adverse to the public interest. Id. at 1246. The court found the first factor was met
because there was a substantial likelihood that the Department of Justice would succeed
on the merits of its claim because the the court believed that by encouraging and
facilitating individuals to illegally import drugs the requisite "causing" under 21 U.S.C.
section 331 is met and that this alone is enough to constitute a substantial likelihood of
success of the merits. Id. at 1247. The court did not have to assess the second and third
factors, dealing with "irreparable injury," because it has long been held that when an
injunction is authorized by the statute, the passage of the statute itself is, in a sense, an
implied finding that any violation will harm the public and ought, if necessary, be
restrained. Id. at 1248. Therefore, the Department of Justice is only required to show
that the defendants have violated the particular statute and that there exists "some
cognizable danger of recurrent violation. Id. The court found that the danger of
"recurrent violation" was present because Carl Moore or Rx Depot testified that he will
not shut down Rx Depot unless a court orders him to do so. Id. at 1250. Lastly, the court
found that the injunction was not adverse to the interest of the public. Although the court
was "not unsympathetic to the predicament faced by individuals who cannot afford their
prescription drugs at U.S. prices," it recognized that Congress, by statute, has already
determined that Rx Depot's business practices harm the public interest. Id. at 1248.
210. The first claim asserted by Rx Depot was its belief that the FDA personal
importation policy amounted to unconstitutional selective enforcement and represented
"geographical" discrimination because individuals in the Northern United States are able
to easily cross the border to obtain cheaper prescription drugs while individuals, farther
from the Canadian border, are being enjoined from doing practically the same thing. Id.
at 1249. The court found this argument to be unpersuasive and held that it was
reasonable for the FDA to marshal its limited resources against large-scale, commercial
operations rather than small-scale individual violators and, therefore, Rx Depot did not
meet the requisite showing for selective enforcement. Id. Secondly, Rx Depot argued
that the FDA's enforcement action violated the Privileges and Immunities Clause, found
in Article IV, Section 2 of the United States Constitution, which requires a state to accord
residents and non-residents equal treatment when regulating the means of livelihood or
doing business. Id. The court rejected this argument because Rx Depot did not show that
it had a privilege or a fundamental right to facilitate illegal prescription drug importation.
Id. Next, the court rejected Rx Depot's assertion that its business practices are protected
"speech" under the First Amendment, holding that any First Amendment interest in
advertising a commercial transaction is "altogether absent when the commercial activity
itself is illegal and the restriction on advertising is incidental to a valid limitation on
economic activity." Id. The last two arguments asserted by Rx Depot were also
discarded by the court: The court held that the North American Free Trade Agreement
(NAFTA) did not protect Rx Depot's right to facilitate importation of drugs because it
was conceded by Rx Depot that NAFTA does not provide a remedy to private citizens.
Id. The court also declined Rx Depot's request for the court to invoke its equitable
powers holding that it would be an abuse of its power to ignore statutory law or to declare
a statute invalid where there is no constitutional basis for doing so. Id. at 1250.
211. Obviously, the Department of Justice's argument coincides with the FDA's
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unsafe because they are not under the constant regulation of the FDA.2 12
The court was very stern in its position that drugs reimported from
foreign countries by someone other than the United States manufacturer
do not have the same assurance of safety and efficacy as drugs regulated
by the FDA.213 In addition, the court criticized Rx Depot's advertising of
the availability of dispensing preset quantities of drugs regardless of the
quantity prescribed by the United States physician, and without
directions to take the drug for only the number of days prescribed by the
physician.214  This gives American patients the ability to take
prescription drugs for a longer period than their United States physician
intended them to do so, which can be dangerous in instances where drugs
have potentially life-threatening side effects with continued use.215
The preliminary injunction granted by the court, pursuant to 21
U.S.C. Section 332(a), restrained and enjoined Rx Depot from directly or
indirectly causing the importation of any article of drug into interstate
commerce. 216  It also barred Rx Depot from offering, advertising, or
promoting any service that causes or facilitates the importation or
assistance in importing articles of drug from any place outside the United
States.217
IV. Conclusion
This comment has attempted to comprehensively analyze the
reimportation debate, discussing the major arguments provided by both
argument, which mirrors the arguments of those who oppose reimportation. See
discussion supra Part I.A.
212. Rx Depot, 290 F.Supp.2d at 1241. The drugs are not subject to FDA oversight
and are not continuously under the custody of a United States manufacturer or authorized
distributor, which makes the drugs' quality less predictable than drugs obtained directly
within the United States. Id. at 1241-42. For instance, the drugs may be contaminated,
counterfeit, or contain erratic amounts of the active ingredient. Also, the drugs may have
been held under uncertain storage conditions, and therefore be outdated or subpotent. Id.
213. Id. Even though the FDA is currently unaware of anyone harmed by prescription
medications ordered through Rx Depot and reimported from Canada, the court believed
that the legitimate safety concerns of the FDA are not diminished. Id. at 1242.
214. Id. at 1242.
215. Id. at 1242-43. An FDA agent made an undercover purchase through Rx Depot.
Even though the agent had a prescription for one hundred pills, the agent was able to
order a quantity of one hundred pills. In addition, the pills arrived without any
instruction of how or how long the patient should take the pills.
216. Id.
217. Id. at 1251. This decision marked the beginning of the end to Carl Moore's
(founder of Rx Depot) attempt to facilitate Americans in securing affordable prescription
drugs by the use of storefront distributors. Associated Press, Rx Depot Drops Drug
Fight, THE WASHINGTON POST, August 21, 2004, at A09. In August of 2004, almost a
year after the decision, Carl Moore realized that he did not have a chance to prevail and
finally consented to the decree making the court's order enjoining the storefront
distributor's permanent. Id.
[Vol. 23:4
TO THE U.S. GOVERNMENT
the proponents and the opponents of reimportation. Further, this
comment presents an evaluation of where individual State's stand on
reimportation and it discusses the action taken by the lone federal court
to rule on the issue of reimportation. What does this all amount to? I
believe it can be summed up in one statement; our government must
realize that it is absolutely appalling that in a country as rich and
powerful as the United States, approximately twenty-nine percent of its
citizens are unable to afford some or all of their necessary prescription
drugs.
2 18
This statement is especially true when looking at America's seniors,
such as Ray Park,219 who have helped make the United States the country
it is today. These American seniors, mostly blue-collar workers, lived
paycheck to paycheck relying on the fact that when they retired, they
would have a full pension and a healthcare plan.22° Is it fair to leave
these life-long, hardworking Americans in the cold simply because the
company they worked forty-plus years for happened to file for
bankruptcy? The majority of Americans, hopefully, would answer this
question in the negative, which makes it even more unbelievable that the
United States government has not adequately addressed this issue.
While the U.S. Government continually debates the appropriate
action it wants to take in order to help Americans afford their necessary
prescription drugs, individuals have been taking the matter into their own
hands by turning to foreign countries, such as Canada, to obtain their
prescription drug needs. Whatever channel of reimportation chosen-
personally traveling across the border, ordering through the Internet, or
by contacting a storefront distributor-Americans are finding out that by
reimporting prescription drugs from foreign countries, they are finally
able to afford their doctor-prescribed medications. Instead of choosing
between prescription drugs and paying for food or rent, Americans are
using reimportation to finally take a full dose of life-saving prescription
drugs.
The United States Government, through the FDA, has criticized
these practices of reimportation, labeling reimportation as very unsafe
and a threat to the U.S. drug distribution system. In fact, the Department
of Justice filed suit in the United States District Court in the Northern
District of Oklahoma to enjoin Rx Depot, a storefront distributor, from
helping Americans obtain affordable prescription drugs from Canada.
22
'
While was done with the intention of keeping the U.S. drug distribution
218. Hall, supra note 13.
219. See supra p.53 n.100.
220. Jones supra note 8.
221. See discussion supra Part III.A.
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system safe, it has hurt those Americans who cannot afford to partake in
the U.S. drug distribution system. These individuals believe an
unaffordable drug is more dangerous than a reimported drug because the
reimported drug at least gives them a chance to fulfill a doctor's
prescription.
Seniors and other reimporters would prefer to stop reimporting
drugs from foreign countries, but the Government has refused to offer an
adequate alternative. An attempt was made with the enactment of the
Medicare Prescription Drug Improvement and Modernization Act (The
Act),222 which adds Part D to Medicare and establishes a new voluntary
prescription drug benefit program. 223  The Act was enacted with the
intent of cutting drug costs by about one-third for the average senior and
to provide medicines virtually free to millions of low-income seniors.
The plan, however, provides little relief for about three million people
with moderate assets and incomes near the poverty level, and would cost
seniors with drug expenses under $835 a year more than they currently
spend.224 It has actually been estimated that about one-quarter of all
seniors became worse off the day the bill was enacted.225  Therefore,
some, if not most, would say that the government has again failed to
adequately address this issue.
Whether or not reimportation is the answer, something must be
done to help Americans afford their necessary prescription drugs. In a
country as rich as the U.S., there is no reason for Americans to
compromise their safety by being forced to choose between reimporting
prescription drugs or not taking the drugs at all. If the Federal
Government steps up and somehow or someway provides American
citizens access to safe, affordable prescription drugs, the entire
reimportation issue would become moot. I, for one, cannot believe this
issue has been ignored for so long. I only hope the U.S. Government
comes to its senses and adequately address this issue by providing all
Americans access to affordable prescription drugs.
222. The Medicare Prescription Drug Improvement and Modernization Act of 2003,
Pub. L. No. 108-173, 117 Stat. 2066.
223. Daniel Katz and Monica Deshpande, An Rxfor the Modification of the Medicare
Prescription Drug, Improvement, and Modernization Act of 2003: Toward a Reform with
Results, 14 ANNALS HEALTH L. 183, 185 (2005).
224. Alice Dembner, Many win, some lose in Medicare drug bill, THE BOSTON
GLOBE, Nov. 18, 2003, available at 2003 WL 66477842 (last visited Feb. 15, 2005).
This article believes that the bill is very adequate for those seniors that originally did not
have any coverage, but those within the middle range will most likely be disappointed.
225. Marilyn Werber Serafini, No Cure-All, NAT'L. J., Nov. 22, 2003, available at
2003 WL 65592514 (last visited Feb. 15, 2005).
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